ABUS Arbutus Biopharma Corp
Price (delayed)
$3.48
Market cap
$666.35M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.38
Enterprise value
$631.31M
Arbutus Biopharma Corporation is a biopharmaceutical company primarily dedicated to discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection. The Company is advancing multiple
Highlights
ABUS's quick ratio is up by 41% YoY and by 17% QoQ
The debt has declined by 27% year-on-year and by 11% since the previous quarter
Arbutus Biopharma's revenue has shrunk by 66% YoY and by 8% QoQ
Arbutus Biopharma's gross profit has shrunk by 66% YoY and by 8% QoQ
Key stats
What are the main financial stats of ABUS
Market
Valuations
Earnings
Shares outstanding
191.48M
Market cap
$666.35M
Enterprise value
$631.31M
Price to earnings (P/E)
N/A
Price to book (P/B)
6.77
Price to sales (P/S)
104.67
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
102.3
Revenue
$6.17M
Gross profit
$6.17M
Operating income
-$73.69M
Net income
-$69.92M
EBIT
-$69.78M
EBITDA
-$68.4M
Free cash flow
-$65.03M
Per share
Balance sheet
Liquidity
EPS
-$0.38
EPS diluted
-$0.38
Free cash flow per share
-$0.35
Book value per share
$0.51
Revenue per share
$0.03
TBVPS
$0.71
Total assets
$131.71M
Total liabilities
$34.34M
Debt
$1.29M
Equity
$97.37M
Working capital
$111.7M
Debt to equity
0.01
Current ratio
8.15
Quick ratio
8.01
Net debt/EBITDA
0.51
Margins
Efficiency
Dividend
EBITDA margin
-1,108.5%
Gross margin
100%
Net margin
-1,133%
Operating margin
-1,194.2%
Return on assets
-48%
Return on equity
-63.4%
Return on invested capital
-82.8%
Return on capital employed
-60.1%
Return on sales
-1,130.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ABUS stock price
How has the Arbutus Biopharma stock price performed over time
Intraday
-0.29%
1 week
3.26%
1 month
0.87%
1 year
35.94%
YTD
6.42%
QTD
-0.29%
Financial performance
How have Arbutus Biopharma's revenue and profit performed over time
Revenue
$6.17M
Gross profit
$6.17M
Operating income
-$73.69M
Net income
-$69.92M
Gross margin
100%
Net margin
-1,133%
The net margin has dropped by 182% year-on-year
ABUS's operating margin has dropped by 178% year-on-year but it is up by 2% since the previous quarter
Arbutus Biopharma's revenue has shrunk by 66% YoY and by 8% QoQ
Arbutus Biopharma's gross profit has shrunk by 66% YoY and by 8% QoQ
Growth
What is Arbutus Biopharma's growth rate over time
Valuation
What is Arbutus Biopharma stock price valuation
P/E
N/A
P/B
6.77
P/S
104.67
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
102.3
The company's EPS rose by 14% YoY and by 12% QoQ
ABUS's price to book (P/B) is 100% higher than its 5-year quarterly average of 3.4 and 23% higher than its last 4 quarters average of 5.5
Arbutus Biopharma's equity has decreased by 9% QoQ and by 8% YoY
The price to sales (P/S) is 197% higher than the 5-year quarterly average of 35.3 and 41% higher than the last 4 quarters average of 74.7
Arbutus Biopharma's revenue has shrunk by 66% YoY and by 8% QoQ
Efficiency
How efficient is Arbutus Biopharma business performance
The company's return on sales has shrunk by 183% YoY
The ROIC has declined by 35% year-on-year but it rose by 4.5% since the previous quarter
Arbutus Biopharma's return on assets has decreased by 11% YoY but it has increased by 7% QoQ
The ROE is down by 10% year-on-year but it is up by 7% since the previous quarter
Dividends
What is ABUS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ABUS.
Financial health
How did Arbutus Biopharma financials performed over time
ABUS's quick ratio is up by 41% YoY and by 17% QoQ
The company's current ratio rose by 39% YoY and by 16% QoQ
The debt is 99% smaller than the equity
ABUS's debt to equity has dropped by 50% year-on-year
The debt has declined by 27% year-on-year and by 11% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.